Trial
NCT02356458
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
European Mantle Cell Lymphoma Network
Condition
Mantle Cell Lymphoma
Intervention
Ibrutinib
Why stopped
SAKK Board decision of 14th November 2020 due to financial reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-11